Fig. 1
From: Pediatric methylation class HGNET-MN1: unresolved issues with terminology and grading
Results of the meta-analysis and prognostic data of HGNET-MN1. (a) Integrative annotation of histopathologic features (mitotic index, microvascular proliferation -MVP- and necrosis), treatment (surgery and adjuvant therapy -adj. Therapy-) and follow-up of our cases and cases of the literature included in the meta-analysis (b) There is no significant difference in terms of PFS and OS between HGNET-MN1 with or without elevated mitotic index (p = 0.094 and 0.461 respectively), microvascular proliferation (p = 0.379 and 0.423, respectively) and necrosis (p = 0.301 and 0.426, respectively).(c) Results of the meta-analysis including 32 ependymomas, RELA-fusion (EPN-RELA, n = 32), HGENT-MN1 (n = 24), 19 ependymomas, YAP1-fusion (EPN-YAP1, n = 19), and HGNET-BCOR (n = 28). Kaplan–Meier estimates of overall survival (OS) and progression free survival (PFS) according to DNA-methylation subgroups: There is a significant difference in terms of PFS (p < 0.001) and OS (p < 0.001) between EPN-RELA, EPN-YAP1, HGNET-BCOR and HGNET-MN1